Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
everolimus 5 endocrinologydiseasesdrugs
multiple endocrine neoplasia 1 endocrinologydiseases
neuroendocrine tumor 2 endocrinologydiseases
sunitinib 2 endocrinologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
everolimus 14400 somatostatin analogs (such as octreotide and lanreotide), peptide receptor radionuclide therapy (PRRT), everolimus and sunitinib, has been reported to improve the survival of patients with unresectable GEP-NETs ([81];
everolimus 20598 (particularly of the insulinoma tumor subtype) and has been used to evaluate the therapeutic potential of everolimus and sunitinib ([17]). The promising preclinical results obtained were subsequently validated in human
everolimus 26075 also been used to develop drugs to treat GEP-NETs. BON1 has been used to test somatostatin analogs and everolimus ([145]; [62]). The KRJ-I cell line, derived from a patient's small-intestinal NET, has been used to
everolimus 27106 allowing for the assessment of their genomic mutations and drug responses (to somatostatin analogs and everolimus ) ([83], [84]). One of these pancreatic lines has a high Ki67 index of 90% and should therefore be considered
everolimus 27359 addition, 16 pancreatic NET primary cell culture lines, including two pancreatic NEC lines that respond to everolimus , have been established by another laboratory ([32]). The creation of these pancreatic NEN cell lines
sunitinib 14415 analogs (such as octreotide and lanreotide), peptide receptor radionuclide therapy (PRRT), everolimus and sunitinib , has been reported to improve the survival of patients with unresectable GEP-NETs ([81]; [100]; [16];
sunitinib 20613 insulinoma tumor subtype) and has been used to evaluate the therapeutic potential of everolimus and sunitinib ([17]). The promising preclinical results obtained were subsequently validated in human clinical trials
Select Disease Character Offset Disease Term Instance
multiple endocrine neoplasia 10451 susceptibility allele is not found). To date, at least four familial GEP-NET syndromes have been reported: multiple endocrine neoplasia type 1 (MEN1), tuberous sclerosis complex (TSC), Von Hippel–Lindau (VHL) and neurofibromatosis type
neuroendocrine tumor 504 of neuroendocrine cell phenotype that mainly fall into one of two subtypes: gastroenteropancreatic neuroendocrine tumor s (GEP-NETs; well differentiated) or gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs; poorly
neuroendocrine tumor 2604 terms). GEP-NENs are broadly classified into two histopathological subtypes: gastroenteropancreatic neuroendocrine tumor s (GEP-NETs) and gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs) (Table 1) ([13]; [71]). Box

You must be authorized to submit a review.